Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Holt, B van der"'
Autor:
Rijneveld, A.W., Holt, B. van der, Weerdt, O. de, Biemond, B.J., Loosdrecht, A.A. van de, Wagen, L.E. van der, Bellido, M., Gelder, M. van, Velden, W.J.F.M. van der, Selleslag, D., Lammeren-Venema, D. van, Halkes, C.J.M., Fijnheer, R., Havelange, V., Sluis, G.L. van, Legdeur, M.C., Deeren, D., Gadisseur, A., Sinnige, H.A.M., Breems, D.A., Jaspers, A., Legrand, O., Terpstra, W.E., Boersma, R.S., Mazure, D., Triffet, A., Tick, L.W., Beel, K., Maertens, J.A., Beverloo, H.B., Bakkus, M., Homburg, C.H.E., Haas, V. de, Velden, V.H.J. van der, Cornelissen, J.J., Dutch-Belgian HOVON Cooperative Gr
Publikováno v:
Blood advances, 6(4). The American Society of Hematology
Blood advances, Vol. 6, no.4, p. 1115-1125 (2022)
Blood advances, 6(4), 1115-1125. American Society of Hematology
Blood Advances, 6, 4, pp. 1115-1125
Blood Advances, 6, 1115-1125
Blood Advances, 6(4), 1115-1125. ELSEVIER
Blood advances
BLOOD ADVANCES
Blood, 6(4), 1115-1125. AMER SOC HEMATOLOGY
Blood advances, Vol. 6, no.4, p. 1115-1125 (2022)
Blood advances, 6(4), 1115-1125. American Society of Hematology
Blood Advances, 6, 4, pp. 1115-1125
Blood Advances, 6, 1115-1125
Blood Advances, 6(4), 1115-1125. ELSEVIER
Blood advances
BLOOD ADVANCES
Blood, 6(4), 1115-1125. AMER SOC HEMATOLOGY
Clofarabine (CLO) is a nucleoside analog with efficacy in relapsed/refractory acute lymphoblastic leukemia (ALL). This randomized phase 3 study aimed to evaluate whether CLO added to induction and whether consolidation would improve outcome in adults
Autor:
Hazenberg, B.P.C., Croockewit, A.J., Holt, B. van der, Zweegman, S., Bos, G.M., Delforge, M., Raymakers, R.A., Sonneveld, P., Vellenga, E., Wijermans, P.W., Borne, P.A. von dem, Oers, M.H. van, Weerdt, O. de, Spoelstra, F.M., Lokhorst, H.M.
Publikováno v:
Haematologica, 100, 5, pp. 677-82
Haematologica, 100, 677-82
Haematologica, 100, 677-82
Contains fulltext : 155242.pdf (Publisher’s version ) (Open Access) In a prospective multicenter phase II study, we evaluated the effect of three courses of vincristine, doxorubicin and dexamethasone followed by high-dose melphalan and autologous s
Autor:
Porcelijn, L., Huiskes, E., Schipperus, M., Holt, B. van der, Haas, M. de, Zwaginga, J.J., Dutch HOVON 64 Study Grp
Publikováno v:
Blood, 129(25), 3389-3391. American Society of Hematology
Blood, 129(25), 3389-3391
Blood, 129(25), 3389-3391
To the editor: Rituximab, a chimeric CD20 monoclonal antibody that causes depletion of B cells, shows short-term treatment efficacy in 40% to 60% of immune thrombocytopenia (ITP) patients.[1][1],[2][2] Our recently published multicenter randomized op
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb6482bc20d0e9fbcc6973aa9888f3c1
https://hdl.handle.net/1887/116039
https://hdl.handle.net/1887/116039
Autor:
Zwaginga, J.J., Holt, B. van der, Boekhorst, P.A. te, Biemond, B.J., Levin, M.D., Griend, R. van der, Brand, A., Zweegman, S., Pruijt, H.F.M., Novotny, V.M.J., Vreugdenhil, A., Groot, M.R. de, Weerdt, O. de, Pampus, E.C.M. van, Maanen-Lamme, T.M. van, Wittebol, S., Schipperus, M.R., Silbermann, M.H., Huijgens, P.C., Luten, M., Hollestein, R., Brakenhoff, J.A.C., Schrama, J.G., Valster, F.A.A., Velders, G.A., Koene, H.R., Dutch HOVON 64 Study Grp
Publikováno v:
Zwaginga, JJ, van der Holt, B, te Boekhorst, P A, Biemond, B J, Levin, M D, van der Griend, R, Brand, A, Zweegman, S, Pruijt, H F M, Novotny, V M J, Vreugdenhil, A, de Groot, M R, de Weerdt, O, van Pampus, E C M, van Maanen-Lamme, T M, Wittebol, S, Schipperus, M R, Silbermann, M H, Huijgens, P C, Luten, M, Hollestein, R, Brakenhoff, J A C, Schrama, J G, Valster, F A A, Velders, G A & Koene, H R 2015, ' Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients ', Haematologica, vol. 100, no. 3, pp. E90-E92 . https://doi.org/10.3324/haematol.2014.110213
Haematologica, 100, e90-2
Haematologica, 100, 3, pp. e90-2
Haematologica-the Hematology Journal, 100(3), E90-E92. Ferrata Storti Foundation
Haematologica, 100(3), E90-E92
Haematologica, 100(3), E90-E92. Ferrata Storti Foundation
Haematologica, 100(3), e90-e92. Ferrata Storti Foundation
Haematologica, 100, e90-2
Haematologica, 100, 3, pp. e90-2
Haematologica-the Hematology Journal, 100(3), E90-E92. Ferrata Storti Foundation
Haematologica, 100(3), E90-E92
Haematologica, 100(3), E90-E92. Ferrata Storti Foundation
Haematologica, 100(3), e90-e92. Ferrata Storti Foundation
The overall short-term treatment efficacy of rituximab (R) in immune thrombocytopenia (ITP) is reported to be approximately 58%.[1][1],[2][2] With four once-weekly 375 mg/m2 doses, responses of 31% after two years,[2][2] and 21% after five years[2][2
Autor:
Zwaginga, J.J., Holt, B. van der, Boekhorst, P.A.W., Biemond, B.J., Levin, M.D., Griend, R. van der, Brand, A., Zweegman, S., Pruijt, H.F., Novotny, V.M.J., Vreugdenhil, A., Groot, M.R. de, Weerdt, O. de, Pampus, E.C.M. van, Maanen-Lamme, T.M. van, Wittebol, S., Schipperus, M.R., Silbermann, M.H., Huijgens, P.C., Luten, M., Hollestein, R., Brakenhoff, J.A., Schrama, J.G., Valster, F.A., Velders, G.A., Koene, H.R.
Publikováno v:
Haematologica, 100, 3, pp. 90-92
Haematologica, 100, 90-92
Haematologica, 100, 90-92
Contains fulltext : 155081.pdf (Publisher’s version ) (Open Access)
Autor:
de Bont, J. M.1, Holt, B. van der2, Dekker, A. W.3, van der Does-van den Berg, A.4, Sonneveld, P.5, Pieters, R.1,4 rob.pieters@erasmusmc.nl
Publikováno v:
Leukemia (08876924). Dec2004, Vol. 18 Issue 12, p2032-2035. 4p.
Autor:
Gahrmann, R., Bent, M. van den, Holt, B. van der, Vernhout, R., Taal, W., Taphoorn, M., Groot, J. de, Beerepoot, L., Jasperse, B., Smits, M.
Publikováno v:
Neuro-Oncology, 18, 9-9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1094223a0de5673c75fc66e7165b123c
https://hdl.handle.net/1887/113093
https://hdl.handle.net/1887/113093
Autor:
Szabo, A., Dinmohamed, A., Holt, B. van der, Versluis, J., Groot, M. de, Zeerleder, S., Schouten, H., Schaap, M., Meijer, E., Petersen, E., Falkenburg, F., Rijneveld, A., Cornelissen, J.
Publikováno v:
Haematologica, 101, 108-109
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::c88998d938baec207f7d892f62ffbd26
https://hdl.handle.net/1887/113819
https://hdl.handle.net/1887/113819
Publikováno v:
British Journal of Cancer. 2/1/99, Vol. 79 Issue 3/4, p483. 8p.
Autor:
Somers, J.A.E., Holt, B. van der, Sintnicolaas, K., Oudshoorn, M., Braakman, E., Petersen, E.J., Marijt, W.A.F., Huisman, C., Groenendijk-Sijnke, M.E., Brand, A., Cornelissen, J.J.
Publikováno v:
Bone Marrow Transplantation, 48, S64-S65
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::ecb0bbf540644a8d56dc085a828b1578
https://hdl.handle.net/1887/99855
https://hdl.handle.net/1887/99855